NPPA asks companies to cut prices of three cancer drugs post tax relief

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed drug manufacturers to reduce the maximum retail price (MRP) of three crucial cancer drugs. This directive follows the government's decision to exempt Trastuzumab Deruxtecan, Osimertinib, and Durvalumab from Customs duty and reduce GST rates on these medications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7QJvgN8
via IFTTT